Vertex Pharmaceuticals Sickle Cell Therapy to be Reimbursed by England's National Health Service

MT Newswires Live01-31

Vertex Pharmaceuticals (VRTX) said Friday it has made a reimbursement agreement with National Health Service England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy.

The reimbursement agreement coincides with the UK National Institute for Health and Care Excellence recommending Casgevy's use by the NHS, the company said.

Administration of the therapy requires experience in stem cell transplantation, and Vertex said it is working with hospitals to establish treatment centers.

Shares of the company were up more than 8% in Friday's premarket activity.

Price: 475.00, Change: +36.60, Percent Change: +8.35

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment